Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria transplants show promise for children with stubborn Crohn's

NCT ID NCT05321745

Recruiting now Disease control Sponsor: Biao Zou Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether repeated fecal microbiota transplants (FMT) from healthy donors, combined with a special liquid diet, can safely help children aged 2–16 with active Crohn's disease that hasn't improved with standard treatments. The goal is to see if this approach can reduce inflammation and bring about remission. The trial tracks both clinical and endoscopic healing, while monitoring for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
fecal microbiota transplantation (FMT) plus partial enteral nutrition (PEN)
What this could lead to
If it works, this could offer a new treatment option for children with Crohn's disease who have not responded to standard therapies.
What could go wrong
This is a small, early-stage study. FMT carries risks like infection or abdominal pain, and the approach may not work for all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tongji Hospital

    RECRUITING

    Wuhan, Hubei, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.